Live Pharmaceutical Import Data of US by HS Code 300490 for US Imports from Spain via port New-york-newark-area-newark-new-jersey. Our US Import Bill of Lading Data and US Import Data by HS Code, country, or port include HS code, date, B/L number, product description, loading and unloading ports, US Importer/exporter name, quantity, etc.
Date |
HS Code |
Product Description |
Origin Country |
Unloading Port |
QTY. |
Unit |
Weight |
Importer Name |
|---|---|---|---|---|---|---|---|---|
| 2024-06-05 | 300490 | PHARMACEUTICALS BULK ASP DAY COLD FLU POWER G EL BLM HS CODE: 300490 INV: 812A485596 812A48 5595 812A485597 812A485594 TEMPERATURE: 19C S POT:23-131WW | SPAIN | NEW YORK NEWARK AREA NEWARK NEW JERSEY | 43 | PKG | 13330 | Importer Name |
| 2024-06-06 | 30049039 | 1X40'HC CONTAINER SAID TO CO NTAIN 1167 CORRUGATED BOXES NON-HAZARDOUS PHARMACEUTICAL FINISH PRODUCT 1167 BOXES INVOICE NO: 197/23-24 INVOIC E DATE: 27-03-2024 PROPOFOL 2 00 MG / 20 ML INJECTION EMULSI ON PACKING: EACH PACK X 1 VIA L MFG DATE: 02/2024 EXP DATE: 01/2026 BATCH NO: PP01I2401, PP01I2402, PP01I2403, PP01I24 04, PP01I2405, HS CODE: 300 49099 CEFOTAXIME FOR INJECTIO N USP 1 GM PACKING: EACH PACK X 1 VIAL MFG DATE: 01/2024 E XP DATE: 06/2026 BATCH NO: CE 10I2401, HS CODE: 30049099 MO XIFLOXACIN HYDROCHLORIDE INFUS ION 400 MG/100 ML PACKING: EA CH PACK X 1 BOTTLE MFG DATE: 02/2024 EXP DATE: 01/2026 BAT CH NO: 2461611B, HS CODE: 300 49039 MELOXICAM INJECTION 15 MG/1.5 ML PACKING: EACH PACK X 5 AMPOULES MFG DATE: 02/202 4 EXP DATE: 01/2027 BATCH NO: MX15I2401, MX15I2403, HS COD E: 30049039 SB NO: 8689858, S B DATE: 28/03/2024 TOTAL NET WEIGHT - 11982.50 KGS FREIGHT PREPAID | SPAIN | NEW YORK NEWARK AREA NEWARK NEW JERSEY | 1167 | BOX | 12901.2912 | Importer Name |
2024-06-05
PHARMACEUTICALS BULK ASP DAY COLD FLU POWER G EL BLM HS CODE: 300490 INV: 812A485596 812A48 5595 812A485597 812A485594 TEMPERATURE: 19C S POT:23-131WW
43
PKG
13330
2024-06-06
1X40'HC CONTAINER SAID TO CO NTAIN 1167 CORRUGATED BOXES NON-HAZARDOUS PHARMACEUTICAL FINISH PRODUCT 1167 BOXES INVOICE NO: 197/23-24 INVOIC E DATE: 27-03-2024 PROPOFOL 2 00 MG / 20 ML INJECTION EMULSI ON PACKING: EACH PACK X 1 VIA L MFG DATE: 02/2024 EXP DATE: 01/2026 BATCH NO: PP01I2401, PP01I2402, PP01I2403, PP01I24 04, PP01I2405, HS CODE: 300 49099 CEFOTAXIME FOR INJECTIO N USP 1 GM PACKING: EACH PACK X 1 VIAL MFG DATE: 01/2024 E XP DATE: 06/2026 BATCH NO: CE 10I2401, HS CODE: 30049099 MO XIFLOXACIN HYDROCHLORIDE INFUS ION 400 MG/100 ML PACKING: EA CH PACK X 1 BOTTLE MFG DATE: 02/2024 EXP DATE: 01/2026 BAT CH NO: 2461611B, HS CODE: 300 49039 MELOXICAM INJECTION 15 MG/1.5 ML PACKING: EACH PACK X 5 AMPOULES MFG DATE: 02/202 4 EXP DATE: 01/2027 BATCH NO: MX15I2401, MX15I2403, HS COD E: 30049039 SB NO: 8689858, S B DATE: 28/03/2024 TOTAL NET WEIGHT - 11982.50 KGS FREIGHT PREPAID
1167
BOX
12901.2912
The database includes shipment-level information such as shipment date, HS code, product description, quantity, value, port details, country of origin & destination, & importer-exporter information for accurate trade analysis of products under HS code 300490 for US pharmaceutical imports from Thailand via Port New-york-newark-area-newark-new-jersey.
Port New-york-newark-area-newark-new-jersey typically refers to a port that is used for handling and forwarding shipments into US, making it important for tracking inland and cross-border trade flows.
It helps businesses understand sourcing patterns, evaluate supplier performance, track pricing trends, and identify demand for pharmaceutical products, enabling better decision-making for trade and market expansion for US pharmaceutical imports from spain under HS code 300490 via Port New-york-newark-area-newark-new-jersey.
Businesses can identify key importers, evaluate supplier competitiveness, track pricing trends, and analyze demand for specific rubber products to make strategic sourcing and expansion decisions.
Importers, exporters, traders, manufacturers, and market analysts can use this data to understand trade patterns, optimize supply chains, identify potential partners, and gain a competitive advantage in the pharmaceutical market.
